Peter Humphrey, MD, PhD, Discusses Histology and Clinical Trial Enrollment in RCC

Video

At the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, Peter Humphrey, MD, PhD, spoke about how enrollment for specific trials in renal cell carcinoma may incorporate a patient’s tumor histology.

CancerNetwork® spoke with Peter Humphrey, MD, PhD, professor of pathology and director of Genitourinary Pathology at Yale School of Medicine in New Haven, Connecticut, about how clinicians can best identify patients with renal cell carcinoma who may be eligible to enroll on a clinical trial. Humphrey spoke about this topic at the 15th Annual Interdisciplinary Prostate Cancer Congress® and Other Genitourinary Malignancies, hosted by Physicians’ Education Resource®, LLC (PER®).

Transcript:

I can’t really speak to clinical trials, there’s so many ongoing. I think the oncologists [may] be the best doctors to speak to that. I would say that as far as trials, it is important to know that histology can influence enrollment. For example, there were trials presented [at the conference] where the enrollment in 1 trial was based upon a diagnosis of papillary renal cell carcinoma. Other times, it’s [based on] enrollment of clear cell versus non–clear cell renal cell [carcinoma]. Again, knowing the classification of renal cell carcinoma can help [physicians] better understand what the specific aim of the trial might be in targeting a specific type of renal cell carcinoma.

Recent Videos
Marc S. Raab, MD, PhD, details how agents like carfilzomib may play a role in treatment after progression on teclistamab-based induction therapy.
The safety profile of teclistamab-based therapy in the MajesTEC-5 trial was expected based on the known compounds employed in each combination.
Ongoing studies in kidney cancer aim to explore determinants of immune-related adverse effects and strategies for mitigating them.
Machine learning-based approaches may play a role in further understanding of how somatic alterations influence responses or resistance to therapy.
Related Content